SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

Novel and potentially groundbreaking therapeutic strategy

10-Jul-2024 - SciRhom GmbH announced the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including ...

Successful exit: adivo joins Zoetis

adivo’s team and platform will strengthen Zoetis’ capabilities in therapeutic antibody drug discovery for companion animals

19-Sep-2023 - adivo GmbH, a leader in discovering species-specific therapeutic antibodies for pets, announced that it is part of Zoetis, the world’s leading animal health company. HTGF and the existing investors OCCIDENT and MorphoSys AG sold their shares as part of the deal. HTGF was one of the first ...

HTGF invests in biotech start-up adivo

Pet therapeutic antibody firm adivo announces closure of seed-financing round

22-Aug-2018 - German biotech company adivo specializing in generating species-specific therapeutic antibodies for companion animals announces that it received a seed financing from three investors. The adivo team aims to address high medical needs in dogs including cancer and chronic inflammation, with the ...

LDC opens branch in Munich

Focus on discovery of therapeutic antibodies

24-Apr-2018 - The Lead Discovery Center GmbH (LDC) has established a branch - LDC Biologics - in the Munich Biocluster. While the team in Dortmund focuses on chemical compounds (small molecules), in Munich the emphasis will be on the development of therapeutic antibodies. LDC Biologics will produce, optimise ...

LEUKOCARE signs cooperation agreement with Sterigenics

19-Nov-2010 - LEUKOCARE AG announced the signing of a cooperation agreement with Sterigenics. As part of this cooperation, LEUKOCARE plans to use their Stabilizing and Protecting Solutions (SPS) technology together with Sterigenics’ irradiation expertise in order to establish new sterilization procedures for ...

BIOTECHNICA 2010 with new focus topics

21-Sep-2010 - BIOTECHNICA 2010 is open for business in Hannover from 5 to 7 October, with new focus topics and more wide-ranging coverage. Europe’s leading biotech and life sciences event focuses on biotech applications in the fields of medicine, pharmaceuticals, food, agriculture, manufacturing industry and ...

MorphoSys Announces Clinical Milestone from Strategic Alliance

Second Clinical Milestone in 2010

05-Jul-2010 - MorphoSys AG announced that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area of musculoskeletal diseases. The news represents the second HuCAL-derived antibody to ...

MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections

21-Oct-2009 - MorphoSys AG announced the formation of a new alliance with Daiichi Sankyo Company, Limited in the discovery and development of therapeutic antibodies for hospital-acquired (nosocomial) infections. Daiichi Sankyo becomes MorphoSys's first collaborator for HuCAL PLATINUM®-based drug discovery in ...

GENEART and MorphoSys Successfully Cooperate in HuCAL PLATINUM Project

19-Dec-2008 - GENEART and MorphoSys announced their successful cooperation in the HuCAL PLATINUM® project. The application of GENEART's proprietary sequence design software GeneOptimizer® and production of significant parts of the antibody library allowed GENEART to make a large contribution to this project, ...

MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease

Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies

28-Nov-2008 - MorphoSys AG and Galapagos NV announced the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis. The alliance spans all ...